127 related articles for article (PubMed ID: 38002473)
1. CSF, Blood, and MRI Biomarkers in Skogholt's Disease-A Rare Neurodegenerative Disease in a Norwegian Kindred.
Aspli KT; Aaseth JO; Holmøy T; Blennow K; Zetterberg H; Kirsebom BE; Fladby T; Selnes P
Brain Sci; 2023 Oct; 13(11):. PubMed ID: 38002473
[TBL] [Abstract][Full Text] [Related]
2. Skogholt's disease-A tauopathy precipitated by iron and copper?
Aspli KT; Holmøy T; Flaten TP; Whist JE; Aaseth JO
J Trace Elem Med Biol; 2022 Mar; 70():126915. PubMed ID: 34959013
[TBL] [Abstract][Full Text] [Related]
3. Trace elements in cerebrospinal fluid and blood from patients with a rare progressive central and peripheral demyelinating disease.
Gellein K; Skogholt JH; Aaseth J; Thoresen GB; Lierhagen S; Steinnes E; Syversen T; Flaten TP
J Neurol Sci; 2008 Mar; 266(1-2):70-8. PubMed ID: 17900623
[TBL] [Abstract][Full Text] [Related]
4. Cerebrospinal fluid in the differential diagnosis of Alzheimer's disease: clinical utility of an extended panel of biomarkers in a specialist cognitive clinic.
Paterson RW; Slattery CF; Poole T; Nicholas JM; Magdalinou NK; Toombs J; Chapman MD; Lunn MP; Heslegrave AJ; Foiani MS; Weston PSJ; Keshavan A; Rohrer JD; Rossor MN; Warren JD; Mummery CJ; Blennow K; Fox NC; Zetterberg H; Schott JM
Alzheimers Res Ther; 2018 Mar; 10(1):32. PubMed ID: 29558979
[TBL] [Abstract][Full Text] [Related]
5. Brain alterations in the early Alzheimer's continuum with amyloid-β, tau, glial and neurodegeneration CSF markers.
Salvadó G; Shekari M; Falcon C; Operto G; Milà-Alomà M; Sánchez-Benavides G; Cacciaglia R; Arenaza-Urquijo E; Niñerola-Baizán A; Perissinotti A; Minguillon C; Fauria K; Kollmorgen G; Suridjan I; Molinuevo JL; Zetterberg H; Blennow K; Suárez-Calvet M; Gispert JD;
Brain Commun; 2022; 4(3):fcac134. PubMed ID: 35702732
[TBL] [Abstract][Full Text] [Related]
6. Iron and copper in progressive demyelination--New lessons from Skogholt's disease.
Aspli KT; Flaten TP; Roos PM; Holmøy T; Skogholt JH; Aaseth J
J Trace Elem Med Biol; 2015; 31():183-7. PubMed ID: 25563774
[TBL] [Abstract][Full Text] [Related]
7. Associations of CSF PDGFRβ With Aging, Blood-Brain Barrier Damage, Neuroinflammation, and Alzheimer Disease Pathologic Changes.
Cicognola C; Mattsson-Carlgren N; van Westen D; Zetterberg H; Blennow K; Palmqvist S; Ahmadi K; Strandberg O; Stomrud E; Janelidze S; Hansson O
Neurology; 2023 Jul; 101(1):e30-e39. PubMed ID: 37137722
[TBL] [Abstract][Full Text] [Related]
8. Association of Serum GFAP with Functional and Neurocognitive Outcome in Sporadic Small Vessel Disease.
Huss A; Abdelhak A; Mayer B; Tumani H; Müller HP; Althaus K; Kassubek J; Otto M; Ludolph AC; Yilmazer-Hanke D; Neugebauer H
Biomedicines; 2022 Aug; 10(8):. PubMed ID: 36009416
[TBL] [Abstract][Full Text] [Related]
9. Glial and neuroaxonal biomarkers in a multiple sclerosis (MS) cohort.
Kalatha T; Hatzifilippou E; Arnaoutoglou M; Balogiannis S; Koutsouraki E
Hell J Nucl Med; 2019; 22 Suppl 2():113-121. PubMed ID: 31802051
[TBL] [Abstract][Full Text] [Related]
10. Biomarkers for central nervous system injury in cerebrospinal fluid are elevated in COVID-19 and associated with neurological symptoms and disease severity.
Virhammar J; Nääs A; Fällmar D; Cunningham JL; Klang A; Ashton NJ; Jackmann S; Westman G; Frithiof R; Blennow K; Zetterberg H; Kumlien E; Rostami E
Eur J Neurol; 2021 Oct; 28(10):3324-3331. PubMed ID: 33369818
[TBL] [Abstract][Full Text] [Related]
11. Cerebrospinal Fluid and Plasma Biomarkers do not Differ in the Presenile and Late-Onset Behavioral Variants of Frontotemporal Dementia.
Marelli C; Hourregue C; Gutierrez LA; Paquet C; Menjot de Champfleur N; De Verbizier D; Jacob M; Dubois J; Maleska AM; Hirtz C; Navucet S; Bennys K; Dumurgier J; Cognat E; Berr C; Magnin E; Lehmann S; Gabelle A
J Alzheimers Dis; 2020; 74(3):903-911. PubMed ID: 32083577
[TBL] [Abstract][Full Text] [Related]
12. Plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross-sectional and longitudinal study in the AIBL cohort.
Chatterjee P; Pedrini S; Doecke JD; Thota R; Villemagne VL; Doré V; Singh AK; Wang P; Rainey-Smith S; Fowler C; Taddei K; Sohrabi HR; Molloy MP; Ames D; Maruff P; Rowe CC; Masters CL; Martins RN;
Alzheimers Dement; 2023 Apr; 19(4):1117-1134. PubMed ID: 36574591
[TBL] [Abstract][Full Text] [Related]
13. Non-neurological surgery and cerebrospinal fluid biomarkers for neuronal and astroglial integrity.
Anckarsäter R; Anckarsäter H; Bromander S; Blennow K; Wass C; Zetterberg H
J Neural Transm (Vienna); 2014 Jun; 121(6):649-53. PubMed ID: 24420082
[TBL] [Abstract][Full Text] [Related]
14. Associations between biomarkers and age in the presenilin 1 E280A autosomal dominant Alzheimer disease kindred: a cross-sectional study.
Fleisher AS; Chen K; Quiroz YT; Jakimovich LJ; Gutierrez Gomez M; Langois CM; Langbaum JB; Roontiva A; Thiyyagura P; Lee W; Ayutyanont N; Lopez L; Moreno S; Muñoz C; Tirado V; Acosta-Baena N; Fagan AM; Giraldo M; Garcia G; Huentelman MJ; Tariot PN; Lopera F; Reiman EM
JAMA Neurol; 2015 Mar; 72(3):316-24. PubMed ID: 25580592
[TBL] [Abstract][Full Text] [Related]
15. Comparison of CSF neurofilament light chain, neurogranin, and tau to MRI markers.
Mielke MM; Przybelski SA; Lesnick TG; Kern S; Zetterberg H; Blennow K; Knopman DS; Graff-Radford J; Petersen RC; Jack CR; Vemuri P
Alzheimers Dement; 2021 May; 17(5):801-812. PubMed ID: 33663022
[TBL] [Abstract][Full Text] [Related]
16. Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer's disease pathology and clinical disease progression.
Clark C; Lewczuk P; Kornhuber J; Richiardi J; Maréchal B; Karikari TK; Blennow K; Zetterberg H; Popp J
Alzheimers Res Ther; 2021 Mar; 13(1):65. PubMed ID: 33766131
[TBL] [Abstract][Full Text] [Related]
17. Cerebrospinal Fluid, MRI, and Florbetaben-PET in Cerebral Amyloid Angiopathy-Related Inflammation.
Renard D; Collombier L; Demattei C; Wacongne A; Charif M; Ayrignac X; Azakri S; Gaillard N; Boudousq V; Lehmann S; Menjot de Champfleur N; Thouvenot E
J Alzheimers Dis; 2018; 61(3):1107-1117. PubMed ID: 29254099
[TBL] [Abstract][Full Text] [Related]
18. Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study.
Fortea J; Carmona-Iragui M; Benejam B; Fernández S; Videla L; Barroeta I; Alcolea D; Pegueroles J; Muñoz L; Belbin O; de Leon MJ; Maceski AM; Hirtz C; Clarimón J; Videla S; Delaby C; Lehmann S; Blesa R; Lleó A
Lancet Neurol; 2018 Oct; 17(10):860-869. PubMed ID: 30172624
[TBL] [Abstract][Full Text] [Related]
19. A pharmacokinetic and biomarker study of delayed-release dimethyl fumarate in subjects with secondary progressive multiple sclerosis: evaluation of cerebrospinal fluid penetration and the effects on exploratory biomarkers.
Edwards KR; Kamath A; Button J; Kamath V; Mendoza JP; Zhu B; Plavina T; Woodward C; Penner N
Mult Scler Relat Disord; 2021 Jun; 51():102861. PubMed ID: 33773271
[TBL] [Abstract][Full Text] [Related]
20. Cerebrospinal fluid markers of neuronal and glial cell damage to monitor disease activity and predict long-term outcome in patients with autoimmune encephalitis.
Constantinescu R; Krýsl D; Bergquist F; Andrén K; Malmeström C; Asztély F; Axelsson M; Menachem EB; Blennow K; Rosengren L; Zetterberg H
Eur J Neurol; 2016 Apr; 23(4):796-806. PubMed ID: 26822123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
